Ivana Ferrero I F, Deborah Rustichelli D R, Sara Castiglia S C, Loretta Gammaitoni L G, Alessandra Polo A P, Marisa Pautasso M P, Massimo Geuna M G, Franca Fagioli F F
Stem Cell Transplantation Laboratory, Regina Margherita Children's Hospital, City of Health and Science of Turin, Italy;
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS, Candiolo, Italy;
EJIFCC. 2023 Oct 16;34(3):220-227. eCollection 2023 Oct.
The Turin Metropolitan Transplant Centre (CIC 305) includes four flow-cytometry laboratories assessing quality control on hematopoietic stem cells (HSC) with different instruments and operators. Therefore, the CD34+ enumeration assay should be validated on a regular basis. We describe here the validation plan to test the inter-laboratory reproducibility of CD34+ enumeration assay, based on the risk analysis. Stabilized blood samples were analysed using Stem-Kit reagent according to manufacturer's instructions and acquired using the Beckman Coulter Navios at Regina Margherita Children's' Hospital (305-1), Beckman Coulter FC500 at Candiolo Cancer Institute FPO-IRCCS (305-2), BD Biosciences FACSLyric™ at S. Luigi Hospital (305-3), and Beckman Coulter Navios EX at Mauriziano Hospital (305-4). The ISHAGE guidelines were followed for estimating % and absolute number of CD34+ cells in single-platform method. For each sample repeatability limit (r), reproducibility error, uncertainty of reproducibility error and coefficient of variation (CV) were reported. The repeated measurements from each laboratory or instrument have a variability, expressed as reproducibility error, lower than the repeatability limit for that single parameter. The corrected reproducibility error is always lower than the repeatability limit except for the percentage value of the "low" count. The analysis of inter-laboratory variance is within the maximum acceptable variance value, and the CV of all measurements for each parameter is less than 8%, indicating low measurement variability among laboratories. Evaluating the overall data, we can conclude that the four laboratories are perfectly aligned and the results are reproducible.
都灵大都会移植中心(CIC 305)包括四个流式细胞术实验室,这些实验室使用不同的仪器和操作人员对造血干细胞(HSC)进行质量控制评估。因此,CD34+计数检测应定期进行验证。我们在此描述基于风险分析的CD34+计数检测实验室间再现性验证计划。按照制造商的说明,使用Stem-Kit试剂对稳定化血液样本进行分析,并在 Regina Margherita儿童医院(305-1)使用贝克曼库尔特Navios、在坎迪奥洛癌症研究所FPO-IRCCS(305-2)使用贝克曼库尔特FC500、在圣路易吉医院(305-3)使用BD Biosciences FACSLyric™以及在毛里齐亚诺医院(305-4)使用贝克曼库尔特Navios EX进行采集。在单平台方法中遵循ISHAGE指南来估计CD34+细胞的百分比和绝对数量。报告了每个样本的重复性限(r)、再现性误差、再现性误差的不确定度和变异系数(CV)。每个实验室或仪器的重复测量具有一定的变异性,以再现性误差表示,低于该单个参数的重复性限。除了“低”计数的百分比值外,校正后的再现性误差始终低于重复性限。实验室间方差分析在最大可接受方差值范围内,每个参数的所有测量的CV均小于8%,表明各实验室间测量变异性较低。评估总体数据,我们可以得出结论,这四个实验室完全一致,结果具有再现性。